On average, the trial successfully found 70% of cancer, in which some cancers were selected more effectively. Breast cancer has the least success rate, only 33%, but ovarian cancer is more successful than expected at a rate of up to 98%.
The widespread adoption of this test is still several years away, but the team is currently conducting a large-scale study with more than 10,000 healthy subjects.
The study is published in the journal Science.
See more: